Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies?
- 1 September 2000
- journal article
- Published by American Society of Hematology in Blood
- Vol. 96 (5) , 1655-1669
- https://doi.org/10.1182/blood.v96.5.1655
Abstract
No abstract availableKeywords
This publication has 199 references indexed in Scilit:
- N-Arylalkyl Pseudopeptide Inhibitors of FarnesyltransferaseJournal of Medicinal Chemistry, 1998
- Developmentally-regulated expression of murine K-ras isoformsOncogene, 1997
- The Ras AntagonistS-Farnesylthiosalicylic Acid Induces Inhibition of MAPK ActivationBiochemical and Biophysical Research Communications, 1997
- Oreganic Acid, a Potent Inhibitor of Ras Farnesyl-Protein TransferaseBiochemical and Biophysical Research Communications, 1997
- Farnesyl-Derived Inhibitors of ras Farnesyl TransferaseBiochemical and Biophysical Research Communications, 1995
- Protein Modification: Palmitoylation in G-protein signaling pathwaysCurrent Biology, 1995
- Proteolytic Processing of Farnesylated Peptides: Assay and Partial Purification from Pig Brain Membranes of an Endopeptidase Which Has the Characteristics of EC 3.4.24.15Biochemical and Biophysical Research Communications, 1994
- How receptor tyrosine kinases activate rasTrends in Biochemical Sciences, 1993
- Permanent conversion of mouse and human cells transformed by activatedras orraf genes to apparently normal cells by treatment with the antibiotic azatyrosineMolecular Carcinogenesis, 1989
- The Molecular Genetics of Philadelphia Chromosome–Positive LeukemiasNew England Journal of Medicine, 1988